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bronchiectasis patients, J Infect (201Summary Background: It is general belief that Non-cystic fibrosis bronchiectasis (NCFB) is
characterized by frequent community-acquired pneumonia. Nonetheless, the knowledge on
clinical characteristics of CAP in NCFBE is poor and no specific recommendations are available.
We aim to investigate clinical and microbiological characteristics of NCFBE patients with CAP.
Methods: Prospective observational study of 3495 CAP patients (2000e2011).
Results: We found 90 (2.0%) NCFBE-CAP that in comparison with non-bronchiectatic CAP (n,
3405) showed older age (mean  [SD], NCFBE-CAP 73  14 vs. CAP 65  19yrs), more vaccina-
tions (pneumococcal: 35% vs. 14%; influenza: 60% vs. 42%), comorbidities (n  2: 43% vs. 25%),
previous antibiotics (38% vs. 22%), and inhaled steroids (53% vs. 16%) (p < 0.05 each). Strepto-
coccus pneumoniae was the most frequent isolate in both groups (NCFBE-CAP 44.4% vs. CAP
42.7%; p Z 0.821) followed by respiratory virus, mixed infections and atypical bacteria.
Considering overall frequencies of the main pathogens (including monomicrobial and mixed in-
fections) Pseudomonas aeruginosa (15.5% vs. 2.9%; p < 0.001) and Enterobacteriaceae (8.8%of Pneumology, Hospital Clinic, Villarroel 170, Barcelona, Spain. Tel.: þ34 932275549.
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bronchiectasis patients, J Infect (201vs. 2.4%; p Z 0.025) were more prevalent in NCFBE-CAP patients than in CAP.
Despite these clinical and microbiological differences, NCFBE-CAP showed similar outcomes
to CAP patients (mortality, length of hospital stay, etc.).
Conclusions: NCFBE-CAP patients are usually older and have more comorbidities but similar
outcomes than general CAP population. Usual CAP pathogens, such as S. pneumoniae, are also
involved in NCFBE-CAP but P. aeruginosa and other Enterobacteriaceae were globally more
frequent than in CAP. Therefore, a wide microbiological investigation should be recommended
in all NCFBE-CAP cases as well as routine pneumococcal vaccination for prevention of pneu-
monia.
ª 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.Introduction
Non-cystic fibrosis bronchiectasis (NCFBE) is defined by the
presence of abnormal and irreversible bronchial widening
secondary to a non-CF cause and is usually characterized
by1 chronic inflammatory disease,2 frequent respiratory in-
fections, including pneumonia1e3 progressive loss of lung
function,4 worsening in quality of life and5 a considerable
economic burden over time.3,4
Few data are available about incidence of NCFBE, but in
the USA an overall prevalence of 52 per 100 000 has been
reported.5
Severe or recurrent pneumonia is considered a potential
cause of bronchiectasis but also the initial clinical mani-
festation of NCFBE despite poor scientific evidence.6e8
Nevertheless, the scientific literature on the prevalence
of pneumonia among NCFBE patients is limited.6,7,9 More-
over, the diagnosis of NCFBE is frequently achieved with a
considerable delay due to the need of an HRCT scan and
many patients may suffer different episodes of pulmonary
infection and a progression in lung damage before the diag-
nosis is confirmed. Therefore, the presence of bronchiec-
tasis is usually considered a risk condition for community-
acquired pneumonia (CAP) although this association has
been clearly demonstrated only for bronchiectasis second-
ary to primary antibody deficiencies.10
In addition, as almost 40e60% of NCFBE patients suffer
chronic airway infection by potential multidrug resistant
(MDR) pathogens,6,11,12 NCFBE patients are considered at
risk of Pseudomonas aeruginosa and current CAP guidelines
consider NCFBE a risk factor for treatment failure due to
inadequate antibiotic coverage.13,14 Unfortunately, the in-
formation on the etiology and outcomes of pneumonia in
NCFBE is extremely scarce nowadays and no specific clinical
recommendations are currently available.
We aimed to investigate clinical characterization, mi-
crobial etiology and outcomes of CAP in NCFBE patients in
comparison with non-bronchiectatic patients with the
objective to clarify clinical recommendations to treat CAP
in NCFBE patients.
Materials and methods
Study population
We prospectively studied 4413 consecutive cases of adults
patients admitted to the emergency department withlverino E, et al., Microbiology and
5), http://dx.doi.org/10.1016/j.suspicion of CAP from 2000 to 2011 in an 850-bed tertiary
care university hospital in Barcelona, Spain. Among these,
we investigated patients with an established or new
diagnosis of NCFBE confirmed by HRCT. The exclusion
criteria were: a) severe immunosuppression, such as in
solid-organ or bone-marrow transplantation or AIDS, or
receiving chemotherapy or other immunosuppressive
drugs (>20 mg prednisone-equivalent per day for 2
weeks); b) hospitalization in the preceding 21 days; c)
active tuberculosis; d) Health care-associated pneumonia
(HCAP) excepting nursing home (although HCAP criteria
were defined in 2005, they had been individually set as
exclusion criteria for our CAP database since 1996), e)
cystic fibrosis and f) cases with confirmed alternative
diagnosis at the end of follow-up. Cystic fibrosis was
systematically ruled out in all bronchiectatic patients in
the study (sweat test and genetic screening according to
European guidelines).15
Definitions
CAP and other definitions are described in the online
supplemental material. Concordant opinions were
required by two independent reviewers (the attending
physician and a medical researcher external to data anal-
ysis) of chest x-rays and CT scans, when available, to
confirm diagnosis of pneumonia and exclude “simple exac-
erbations of NCFBE or any other chronic respiratory dis-
ease (COPD, etc.)”.
NCFBE was defined clinically and radiologically and not
related to CF, and was confirmed by high-resolution
computerized tomography (HRCT). CT scan had been
performed before CAP episode or during hospital admission
or CAP follow-up by the attending physician for two main
reasons: late response to treatment or diagnostic screening
due to clinical and/or radiological suspicion (chest X-rays)
of bronchiectasis and/or other subsistent respiratory dis-
ease. Chronic bronchial infection was defined as at least 2
respiratory isolates of the same pathogen in the last year (3
months apart) before pneumonia.16
Data collection and follow-up
Data collection during hospital admission (including de-
mographics, comorbidities, previous vaccinations and anti-
microbial therapy, signs and symptoms of clinical
presentation, complete and systematic microbiologicaloutcomes of community acquired pneumonia in non cystic-fibrosis
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CAP in NCFBE 3investigations, antimicrobial therapy and steroids) and
follow-up is widely described in the online supplemental
material.17 All surviving patients were re-examined or at
least telephonically contacted 4e6 weeks after discharge
from the emergency care unit in the outpatients’ clinic in
order to assess clinical resolution (30-day mortality rate).
PSI and CURB-65 classes were assigned according to the
original authors’ designations.
Antibiotic therapy was recorded in all cases and its
adequacy to current Spanish guidelines for CAP18 treatment
was evaluated such as its appropriateness19,20 according to
microbiological findings in those patients with a known mi-
crobial etiology of pneumonia.
The prospective collection of clinical data was approved
by the Institutional Review Board. Patients’ identification
remained anonymous and informed consent was considered
unnecessary due to the observational nature of the study.
All reported data are the result of the clinical routine
activity and all tests and procedures were ordered by the
attending physicians, not involved in this study.Statistical analysis
We performed a secondary analysis of a prospectively
analysis collected CAP database in order to investigate
NCFBE subgroup. We show n (%) for categorical variables
and median (IQR) for continuous variables with non-
normal distribution or mean  SD for those with normal
distribution. Categorical variables were compared with
the chi-square test or Fisher’s exact test. Continuous
variables were compared using the Student’s t-test or the
nonparametric ManneWhitney U test. Univariate and
multivariate logistic regression analyses were performed
to identify variables available at presentation in the
emergency room of our Hospital that predicted hospital-
ization, ICU admission (dependent variable, see online
supplemental material) 30-day mortality and prolonged
length of stay (LOS>7 days; cut-off value the median
value of LOS).
Univariate and multivariate logistic regression analyses
were performed to identify variables predictive of patients’
hospitalization, ICU admission, 30-day mortality and pro-
longed LOS (dependent variables). The variables analyzed
univariately were: age (<65 vs. 65 years), gender, smok-
ing, influenza vaccination, pneumococcal vaccination,
inhaled corticosteroids, previous antibiotic, bronchiectasis,
COPD, chronic cardiovascular disease, diabetes mellitus,
neurological disease, chronic renal disease, chronic liver
disease, cough, sputum, dyspnoea, chest pain, fever,
altered mental status, PSI class (I-III vs. IV-V), CURB-65 (1-
2 vs. 3-5), serum creatinine (<1.5 vs. 1.5 mg/dL), C-RP
(<18 vs. 18 mg/dL[median]), WBC count (<4 vs.
4  109 cell/L), platelets count (<100 vs.
100  109 cell/L), respiration rate (<30 vs. 30 breaths
per min.), systolic blood pressure (<90 vs. 90 mmHg),
temperature (<36 vs. 36 C), SatO2 (<92 vs. 92%),
PaO2/FiO2 (<250 vs. 250), pleural effusion, multilobar
infiltration, ARDS, acute renal failure, etiology, and
bacteraemia.
Variables that showed a significant result univariately
(p < 0.1) were included in the corresponding multivariatePlease cite this article in press as: Polverino E, et al., Microbiology and
bronchiectasis patients, J Infect (2015), http://dx.doi.org/10.1016/j.logistic regression backward stepwise model. Variables
highly correlated were excluded from multivariate ana-
lyses. The HosmereLemeshow goodness-of-fit test was
performed to assess the overall fit of the model21. All tests
were two-tailed and significance was set at 5%. All analyses
were performed with IBM SPSS Statistics 18.0 (Armonk, New
York, USA).Results
General characteristics of the study population
After excluding patients with immunodepression and noso-
comial pneumonia (previous hospitalization in the last 3
months) we analyzed 3731 CAP and NCFBE were described
in 124 patients but they were confirmed by HRCT only in 111
cases (3.0%) (Fig. 1). Overall, 188 patients had more than
one episode of CAP during the study period (162 patients
with 2 episodes of pneumonia, 26 with 3 episodes) but
only first episode was considered for the final analysis. It
is worth noting that NCFBE patients had significantly more
recurrent pneumonia (mean rate of CAP 1.23; n of recur-
rent CAP, 21 [18.9%]) than non-bronchiectatic patients
(mean rate 1.059; n of recurrent CAP, 202 [5.6%])
(p < 0.001). We finally analyzed 3495 patients including
3405 CAP and 90 NCFBE-CAP patients.
A total of 52 (58%) NCBE-CAP patients had an NCFBE
diagnosis prior to pneumonia, whereas 38 (42%) patients
were diagnosed during the current CAP episode by HRCT
scan showing diffuse multilobar bronchiectasis also
affecting lobes not involved in pneumonia, that were
considered, therefore, pre-existing to pneumonia. Data of
clinical history, clinical presentation and outcomes from
patients diagnosed of NCFBE before and during CAP were
compared, showing no significant differences between the
2 groups (on-line supplement Table 1b).
To further confirm the homogeneity of NCFBE patients
(diagnosed before or during CAP) we exclusively compared
NCFBE patients diagnosed before pneumonia (n, 52) with
CAP group (on-line supplement Table 1b) and found no dif-
ferences from the overall analysis including all NCFBE pa-
tients (Tables 1 and 2).
Globally, the underlying etiologies of bronchiectasis
were: idiopathic 27 (30%), previous tuberculosis 28 (31%),
other post-infectious causes 8 (9%), primary immunological
abnormalities 5 (6%), COPD 17 (19%), asthma 3 (3%), ciliary
dyskinesia 1 (1%), MouniereKuhn syndrome 1 (1%).Comparison of CAP and CAP-NCFBE patients
The differences in baseline characteristics between pa-
tients with CAP and those with CAP and NCFBE are
summarized in Table 1. The NCFBE group showed older
age and more females, higher rates of vaccinations,
more comorbidities and previous treatment with inhaled
(ICs), oral corticosteroids and antibiotics in the last month.
Moreover, NCFBE patients presented more expectoration,
dyspnoea, and leukocytosis and needed more hospitaliza-
tion but showed similar PSI and CURB-65 scores (Tables 1
and 2).outcomes of community acquired pneumonia in non cystic-fibrosis
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Figure 1 Flow diagram of the selected population. Abbreviations: NCFBE, non-cystic fibrosis bronchiectasis; CAP, community-
acquired pneumonia; COPD, chronic obstructive pulmonary disease; CT, computed tomography.
4 E. Polverino et al.Microbial etiology
Microbiological diagnosis was achieved in 41.1% of CAP
patients (n, 1399) and in 50.0% (n, 45) of NCFBE-CAP
subgroup (p Z 0.091).
Streptococcus pneumoniae was largely the most preva-
lent causative pathogen of CAP in both groups, followed
by respiratory virus, mixed infections and atypical bacteria
(Table 3). Among cases of polymicrobial infection P. aerugi-
nosa (plus other) was more frequent in NCFBE-CAP (13.3%)
than in CAP (1.0%; p < 0.01), while other combinations
(with S. pneumoniae [8.9% vs. 8.3], Haemophilus influen-
zae [4.4% vs. 2.9%], etc.) were similarly distributed be-
tween the two groups.
Table 4 shows the overall prevalence rates of main path-
ogens as isolated alone (monomicrobial pneumonia) and/or
in combination with any other pathogen (mixed infection),
P. aeruginosa and Enterobacteriaceae being more frequent
among NCFBE-CAP than in CAP.
Only 10 NCFBE patients (11.1%) had a known chronic
bronchial infection prior to the pneumonia episode (6 cases
of P. aeruginosa, 2 of MSSA; 1 of Escherichia coli, 1 H. influ-
enzae): in 3 of them the “chronic” microorganism coincided
with etiology of pneumonia and in 4 cases the “chronic”
microorganism was isolated in CAP as well, but in associa-
tion with a new pathogen; globally 7 of 10 cases of chronic
bronchial infection showed the same pathogen during CAP.
Antibiotic treatment
Data on antibiotic treatment were available in 3462 (99%)
patients. The most frequent regimens were beta-lactamPlease cite this article in press as: Polverino E, et al., Microbiology and
bronchiectasis patients, J Infect (2015), http://dx.doi.org/10.1016/j.plus macrolide (n Z 1188, 34.3%), fluoroquinolone mono-
therapy (n Z 916, 26.5%), fluoroquinolones plus beta-
lactam (n Z 758, 21.9%). These regimens were similarly
administered in patients with and without NCFBE (all,
p > 0.05).
Antibiotic therapy was adequate (according to current
Spanish guidelines for CAP treatment18) in most cases but
less frequently in NCFBE-CAP than in CAP (NCFBE-CAP,
77.8% vs. CAP, 89.0% of cases; p Z 0.020), mostly because
of the administration of a combination of a beta-lactam
plus a glycopeptide or an aminoglycoside (covering possible
MDR infections). However, the antibiotic therapy was also
appropriate in relation with microbial etiology in most
cases of CAP (93.8%, n Z 1069) and NCFBE-CAP (87.8%,
n Z 36; p Z 0.126).
Among cases of P. aeruginosa infection, there was a rate
of appropriate therapy (according to microbial etiology) of
43% (3 out of 7 cases) in NCFBE-CAP and 33% (13 out of 40
cases) in the CAP group (p Z 0.680); this mild and non sig-
nificant difference was due to the increased trend to cover
potential MDR pathogens among NCFBE patients, compared
to CAP.Outcomes and prognostic factors
A non significant trend to increased hospitalization (partic-
ularly ICU) was observed in the NCFBE-CAP group, but no
differences were observed in mortality and/or any other
severity marker such as MV, LOS, pulmonary and systemic
complications of pneumonia between the two groups
(Table 2), despite significant differences in age and number
of comorbidities.outcomes of community acquired pneumonia in non cystic-fibrosis
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Table 1 Characteristics of patients with and without Non-CF Bronchiectasis (n Z 3495).
Variable NCFBE-CAP (n Z 90) CAP (n Z 3405) p-Valuea
Demographic
Age (years), mean  SD 73  14 65  19 0.001
Age 65 years, n (%) 73 (81) 1996 (58.6) <0.001
Sex (male), n (%) 31 (34.4) 22,087 (61.3) <0.001
Smoking, n (%) <0.001
No smoker 56 (62.2) 1512 (44.8)
Current smoker 6 (6.7%) 860 (25.5)
Ex-smoker 28 (31.1) 1005 (29.8)
Alcohol, n (%) 0.133
No alcohol consumer 80 (89.9) 2732 (81.6)
Current alcohol consumer 9 (8.2) 495 (14.8)
Ex-alcohol consumer 35 (2.7) 122 (3.6)
Previous antibiotic, n (%) 32 (37.6) 711 (21.8) <0.001
Nursing home residence, n (%) 3 (3.3%) 82 (2.4) 0.584
Influenza vaccine, n (%) 42 (60.0) 1167 (41.5) <0.001
Pneumococcal vaccine, n (%) 24 (34.8) 397 (14.2) <0.001
Inhaled corticosteroid, n (%) 47 (52.8) 525 (15.6) <0.001
Systemic corticosteroid, n (%) 4 (5.1) 47 (1.5) 0.012
Number of comorbidities ‡2, n (%) 39 (43.3) 847 (24.9) <0.001
Chronic cardiovascular disease 17 (18.9) 586 (17.3) 0.693
Diabetes mellitus 10 (11.5) 544 (16.5) 0.210
Neurological disease 13 (14.4) 596 (17.7) 0.428
Chronic renal disease 6 (6.7) 209 (6.2) 0.847
Haemodialysis 0 (0) 7 (0.2%) 1.000
Chronic liver disease 6 (6.7) 147 (4.3) 0.288
COPD 17 (19.0) 507 (14.9) 0.373
Clinical findings, n (%)
Cough 76 (84.4) 2748 (79.7) 0.259
Sputum 66 (75.0) 1877 (56.9) <0.001
Dyspnoea 70 (78.8) 2188 (65.3) 0.009
Chest pain 38 (42.2) 1396 (41.8) 0.937
Fever 76 (87.4) 2684 (82.73) 0.252
Altered mental status 13 (14.4) 608 (18.0) 0.389
Vital signs
Respiration rate (breaths per min.), median (IQR) 24.5 (20.0e32.0) 24.0 (20.0e30.0) 0.276
Respiration rate 30 breaths per min., n (%) 25 (29.8) 878 (28.2) 0.754
Temperature (C), median (IQR) 37.6 (36.6e38.2) 37.6 (36.6e38.3) 0.307
Temperature <36 C, n (%) 4 (4.9) 185 (5.9) 0.673
Systolic blood pressure (mmHg), median (IQR) 139.5 (116.5e154.0) 130.0 (114.0e149.0) 0.051
Systolic blood pressure <90 mmHg, n (%) 1 (1.1) 129 (3.9) 0.108
Laboratory findings
Creatinine (mg/dL), median (IQR) 1.0 (0.8e1.2) 1.0 (0.9e1.4) 0.059
C-reactive protein level (mg/dL), median (IQR) 16.0 (5.0e23.7) 17.7 (8.9e27.1) 0.074
C-reactive protein level 18 mg/dL, n (%) 33 (45.2) 1349 (49.4) 0.482
WBC count (3109 cell/L), median (IQR) 14.7 (9.9e19.7) 12.6 (8.9e17.3) 0.017
Leukopenia (<4  109 WBC/L), n (%) 0 (0) 96 (2.9) 0.104
Platelets count (109 cell/L), median (IQR) 260.0 (175.0e346.0) 237.0 (184.0e302.0) 0.250
Thrombocytopenia (<100  109 cell/L), n (%) 0 (0) 54 (2.7) 0.212
SatO2<92% in room air, n (%) 21 (40.4) 655 (33.5) 0.522
PaO2/FIO2, median (IQR) 273.0 (238.1e309.5) 285.7 (242.9e333.3) 0.232
PaO2/FIO2 <250, n (%) 21 (37.5) 665 (28.0) 0.118
Abbreviations: IQR Z interquartile range; SD Z standard deviation; PaO2/FIO2 Z arterial oxygen tension to inspired oxygen fraction
ratio; PSI Z pneumonia severity index; SatO2 Z oxygen saturation; WBC Z white blood cells.
Percentages calculated on non-missing data.
Variables with p-values<0.05 are in bold.
a Chi-square test, Fisher’s exact test, Student’s t-test or ManneWhitney U test, as appropriate. Median of C-RP values was used as cut-
off value.
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Table 2 Severity and clinical outcomes of patients with (n, 90) and without Non-CF Bronchiectasis (n Z 3405).
NCFBE-CAP
(n Z 90)
CAP
(n Z 3405)
p-Valuea
PSI classes IV-V, n (%) 50 (55.6) 1672 (49.1) 0.227
CURB-65 classes 3-5, n (%) 8 (11.0) 524 (19.4) 0.071
Bacteraemia, n (%) 4 (4.4) 297 (8.7) 0.153
Multilobar infiltration, n (%) 17 (22.4) 628 (21.5) 0.859
Pleural effusion, n (%) 14 (13.5) 452 (13.5) 0.511
ARDS criteria, n (%) 1 (1.2) 93 (3.1) 0.336
Site of care 0.055
Outpatients 7 (7.8) 551 (16.2) 0.017
Ward 63 (70.0) 2297 (67.5) 0.351
ICU admission, n (%) 20 (22.2) 557 (16.4) 0.094
Mechanical ventilation, n (%) 5 (5.6) 214 (6.3) 0.778
Septic shock, n (%) 4 (4.4) 179 (5.3) 0.708
Acute renal failure, n (%) 19 (21.1) 793 (24.0) 0.527
Length of hospital stay (days), median (IQR) 7.0 (5.0e9.5) 6.0 (3.0e10.0) 0.158
30-day mortality, n (%) 4 (4.4) 246 (7.2) 0.312
Abbreviations: ARDS Z acute respiratory distress syndrome; CURB-65 Z confusion, blood-urea nitrogen, respiratory rate, blood pres-
sure, age; ICU Z intensive care unit; IQR Z interquartile range.
Percentages calculated on non-missing data.
Variables with p-values<0.05 are in bold.
a Chi-square test, Fisher’s exact test or ManneWhitney U test, as appropriate.
6 E. Polverino et al.However, we performed multivariate analyses for ICU
admission, prolonged LOS (>7 days, median LOS of overall
population) and 30-day mortality, but none of them showed
NCFBE to be an independent associated factor, even afterTable 3 Distribution of the causative microorganisms in patien
Microorganism NCFBE-CAP
(n Z 45)
Streptococcus pneumoniae 20 (44.4)
Respiratory virus 4 (8.9)
Mixed 8 (17.8)
Atypical bacteria 2 (4.4)
Mycoplasma pneumoniae 1 (2.2)
Chlamydophila pneumoniae 1 (2.2)
Coxiella burnetii 0 (0)
Legionella pneumophila 1 (2.2)
Pseudomona aeruginosab 1 (2.2)
Enterobacteriaceae
Escherichia coli 2 (4.4)
Klebsiella pneumoniae 0 (0)
Proteus mirabilis 0 (0)
Providencia stuartii 0 (0)
Haemophilus influenzae 2 (4.4)
Moraxella catarrhalis 0 (0)
Haemophilus parainfluenzae 0 (0)
Staphylococcus aureus 3 (6.7)
Others Streptococcus species 2 (4.4)
Streptococcus constellatus 1 (2.2)
Streptococcus viridans 1 (2.2)
Streptococcus pyogenes 0 (0)
Others 0 (0.0)
Data are expressed as n (%).
a Chi-square test or Fisher’s exact test, as appropriate.
b P. aeruginosa when isolated alone.
Please cite this article in press as: Polverino E, et al., Microbiology and
bronchiectasis patients, J Infect (2015), http://dx.doi.org/10.1016/j.adjustments for NCFBE and potential confounding factors
such as previous comorbidities, vaccinations, smoking
habits, alcohol consumption and age (online supplement,
Tables 2b,3b,4b).ts with a defined pneumonia aetiology (n Z 1444).
CAP
(n Z 1399)
p-Valuea
598 (42.7) 0.821
206 (14.7) 0.274
180 (12.9) 0.335
115 (8.2) 0.576
54 (3.9) 1.000
39 (2.8) 1.000
22 (1.6) 1.000
100 (7.1) 0.163
26 (1.9) 0.578
123 (0.9) 0.068
6 (0.4) 0.827
1 (0.1) 0.969
1 (0.1) 1.000
43 (3.1) 0.413
5 (0.4) 0.853
1 (0.1) 0.969
28 (2.0) 0.069
16 (1.0) 0.106
2 (0.1) 0.091
9 (0.6) 0.272
5 (0.4) 1.000
61 (4.4) 0.139
outcomes of community acquired pneumonia in non cystic-fibrosis
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Table 4 Overall frequencies of main isolated microorganisms (monomicrobial and mixed infections).
NCFBE-CAP
n, %
CAP
n, %
p-value
Streptococcus pneumoniae 24 53.3% 714 51.0% 0.885
Pseudomonas aeruginosa 7 15.5% 40 2.9% <0.001
Haemophilus influenzae 4 8.8% 83 5.9% 0.618
Respiratory viruses 6 13.3% 290 20.7% 0.308
Atypical pathogens 2 4.4% 149 10.7% 0.279
Enterobacteriaceae 4 8.8% 33 2.4% 0.025
Staphylococcus aureus 4 8.8% 50 3.6% 0.157
Legionella pneumophila 1 2.2% 111 7.9% 0.266
Note: Percentages refer to cases with known microbial etiology (NCFBE-CAP: 45, CAP: 1399).
Atypical pathogens include: Mycoplasma pneumoniae, Coxiella burnetii, Chlamydia pneumoniae.
Enterobacteriaceae include: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii.
Variables with p-values<0.05 are in bold.
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The main findings of this study were the following:
- Despite an older age and more comorbidities, NCFBE
patients showed a similar clinical presentation at
admission and similar severity scores (PSI, CURB-65).
- Moreover NCFBE patients also showed similar outcomes
(mortality, MV, LOS, etc.) in comparison to the general
CAP population.
- The microbiological investigation showed that S. pneu-
moniae was the most frequent isolate in both groups,
but in the NCFBE-CAP patients there was an overall
(monomicrobial and polymicrobial infections) increased
rate of P. aeruginosa and Enterobacteriaceae compared
to CAP.
- The NCFBE-CAP group showed a lower rate of adequate
empiric antibiotic therapy according to guidelines18 in
comparison with CAP.
This is the first study in the literature analyzing a large
CAP series to investigate demographics, clinical character-
istics and microbial etiology of pneumonia in NCFBE
patients. This study clearly shows that NCFBE-CAP patients
in Spain differ from the general CAP population in different
aspects. In particular, NCFBE-CAP patients showed older
age, more comorbidities and, consequently, increased
vaccination rates (pneumococcal and influenza) and more
inhaled (ICs) and systemic corticosteroids and previous
antibiotic use than CAP population.
Our NCFBE-CAP population, did not show worse clinical
outcomes (mortality, LOS etc.) in comparison with CAP
albeit older age and more comorbidities. Therefore, it is
questionable whether previous antibiotics, steroids and
vaccinations could play a protective role in modulating
pneumonia severity or whether the usual heterogeneity of
NCFBE etiology and severity could also influence overall
clinical presentation of pneumonia. Nevertheless it is
important to consider that patients with an underlying
chronic disease (respiratory or not) might seek health care
earlier and with milder infections than previously healthy
patients that might prefer home care or attend a hospital
on a later stage. Indeed, there are limited studies in thePlease cite this article in press as: Polverino E, et al., Microbiology and
bronchiectasis patients, J Infect (2015), http://dx.doi.org/10.1016/j.literature describing outcomes for hospitalized NCFBE
patients: in 2 studies on ICU patients the reported mortality
rates were 40e60% at 1e4 yrs but no specific data are
reported about the role of CAP in these patients22,23; on the
other hand Seitz et al.24 described an in-hospital mortality
rate of 4.6% for NCFBE hospitalizations recorded in USA be-
tween 1993 and 2006, being pneumonia and influenza the
main cause of death (31%).
Interestingly, despite a greater prevalence of ICs among
our NCFBE-CAP patients, their use did not show any asso-
ciation with main outcomes (mortality, LOS, etc.), but only
with the risk of hospitalization (not ICU). However, both ICs
and systemic steroids have demonstrated some protective
role in general CAP by reducing its severity and the
frequency of complications.25e33 Chronic ICs are largely
used in NCFBE patients but their role in infections (exacer-
bations, pneumonia and chronic infections) should be
surely further investigated.
The microbiological investigation showed that the ma-
jority of NCFBE-CAP are properly covered by current
antimicrobial recommendations (CAP guidelines) but a
greater prevalence of P. aeruginosa and Enterobacteria-
ceae was described in this population. These findings
show that microbiological investigation is particularly
important in NCFBE patients with pneumonia indepen-
dently of initial severity to reduce the risk of treatment
failure but surely more investigation is needed for the
future to provide specific recommendations for clinical
management of acute infections in NCFBE. In fact, accord-
ingly to the literature, it is likely that in an NCFBE cohort
(and not a CAP cohort) the prevalence of P. aeruginosa
could be even higher and influence outcomes more consis-
tently, as it has been demonstrated for chronic P. aerugi-
nosa infection on lung function, exacerbations and
mortality of NCFBE (ref), but the prognostic role of this
pathogen in acute infections has to be better defined yet.
Concordantly, the lower proportion of adequate therapy
in NCFBE-CAP (compared to CAP) and the increased rate of
empiric antibiotic therapy directed at covering potential
MDR pathogens could be possibly interpreted on the base of
reported risk of P. aeruginosa and MDR pathogens in this
population6,11,12 and because of the lack specific recom-
mendations for NCFBE. Nonetheless, mortality rates were
similar in both groups indicating that no significantoutcomes of community acquired pneumonia in non cystic-fibrosis
jinf.2015.03.009
8 E. Polverino et al.consequences were reported in our NCFBE population likely
due to prompt antibiotic changes when needed.
Different guidelines for CAP and low respiratory tract
infections13,14,34 describe a number of risk factors for P.
aeruginosa infection (tobacco, alcohol, malnutrition,
recent hospitalization, frequent hospitalization, frequent
or recent use of antibiotics, FEV%<30%, oral steroids) but
no specific information is provided for NCFBE patients
that are considered themselves at risk for this infection34
independently of their huge etiological and clinical hetero-
geneity. Only the series of 155 NCFBE patients from Mc Don-
nell et al. showed that low FEV1% and polymicrobial
colonization are associated conditions with P. aeruginosa
infection and that it occurs across all strata of lung function
impairment.35 Arancibia et al. showed that the main risk
factors for P. aeruginosa in CAP where pulmonary comor-
bidities (OR: 5.8) and a previous hospital admission (OR:
3.8) but no specific mention is given for NCFBE.36 Unfortu-
nately no other data are currently available in the litera-
ture about risk factors for P. aeruginosa in NCFBE and
particularly in CAP. For all these reasons further investiga-
tion is surely needed in NCFBE in order 1) to assess specific
risk factors for P. aeruginosa and worse outcomes, 2) to
guide antimicrobial therapy in both pneumonia and
exacerbations.
Potential limitations of this study are: only one center
was involved in the study which may not be representative
of other regions, particularly considering the varied
geographical distribution of NCFBE prevalence around the
world; this is a retrospective analysis of a prospective data
collection of CAP cases that was not primarily designed to
investigate NCFBE therefore we are probably underestimat-
ing NCFBE prevalence since CT scan is usually not per-
formed in all CAP patients. Moreover, the observational
nature of this work intrinsically implies the risk of some risk
of selection bias of the patients described in the study
(such as the presence of comorbidities and related treat-
ments, the ease of access to health facilities, local health-
care organization, etc.). Similarly, since our database was
initially designed for CAP, HCAP cases are not included in
our analysis with the exception of haemodialysis (when
immunocompetent) and nursing home patients, that in our
country have been demonstrated to have similar etiology to
CAP.37 In particular patients with previous hospitalizations
were considered affected by nosocomial infections and
therefore excluded, while unfortunately the variables
“home infusion therapy”, “wound care” and “contact
with a family member with known MDR pathogen” were
not recorded in our database.
In summary:
 The NCFBE-CAP patients from our population were
older and had more comorbidities but showed similar
presentation and similar outcomes compared to the
general CAP population; nevertheless an extrapolation
of these results to the general NCFBE patients cannot
be done without the support of further longitudinal
studies based on NCFBE cohorts.
 The microbial etiology of NCBE-CAP was similar to CAP,
S. pneumoniae being the most frequent isolate; none-
theless bronchiectatic patients showed more P. aerugi-
nosa and Enterobacteriaceae than CAP.Please cite this article in press as: Polverino E, et al., Microbiology and
bronchiectasis patients, J Infect (2015), http://dx.doi.org/10.1016/j. Consequently, we suggest a wide microbiological inves-
tigation should be always performed in NCFBE-CAP
independently of initial severity, in order to reduce
the risk of treatment failure and to avoid overuse of
broad-spectrum antibiotics.
 Pneumococcal vaccination should be widely recommen-
ded in bronchiectatic patients considering the preva-
lence of this microorganism in CAP and chronic
bronchial infection.Acknowledgments and funding
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